jeudi 17 octobre 2019

Onco Actu du 17 octobre 2019


1. BIOLOGIE



Changes in Chromosome Caps May be A Marker for Tumor Aggression in Neurofibromatosis Type 1 [Johns Hopkins]











1.1 BIOLOGIE - GÉNOME



$3.7 million supports crowdsourced database of cancer genomics [WUSTL]











1.3 PRIX NOBEL



Nobel Prize for Medicine 2019: Oxygen sensing in cancer [Institute of Cancer Research]











3.1 PRÉVENTION - TABAC



It’s time to eliminate all flavored cigarettes, not just the electronic kind [STAT]










3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE



Expert Panel: Cancer Treatment Plans Should Include Tailored Exercise Prescriptions [American College of Sports Medicine]










New international exercise guidelines for cancer survivors [University of British Columbia]











Exercise Advice for Surviving Cancer, and Maybe Avoiding It [NY Times]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



NHS to offer women mammograms and smears in lunch breaks in bid to boost cancer survival rates [The Telegraph]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Glowing particles in the blood may help diagnose and monitor brain cancer [Mass. General Hospital]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Genetic tests: Experts urge caution over home testing [BBC News]











5.10 TRAITEMENTS - ESSAIS



Lilly's Armo buyout drug a bust in pancreatic cancer [Fierce Biotech]











Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test [Xconomy]











Lilly cancer drug pipeline hit by trial setback [Biopharma Dive]











Eli Lilly’s first PhIII showdown for their $1.6B cancer drug just flopped — what now? [EndPoints]










Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival [Lilly]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Inactive receptor renders immunotherapies ineffective [Technical University of Munich]











5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



VHIO: driving the development of pioneering cell therapies for non-responders to current immunotherapies [VHIO]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Cell therapy player GammaDelta spins off Adaptate to direct body's surveillance system [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



MedImmune's top cancer researcher jumps ship to small biotech [Fierce Biotech]











5.2 PHARMA



Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer [AstraZeneca]











5.2.3 PHARMA - ÉCONOMIE



With biosimilar threat under control (for now), Roche savors demand for its new drugs [EndPoints]











6.1 OBSERVATION



IUDs associated with lower ovarian cancer risk [Reuters]